Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2021-03-11 Annual Report
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2020
2021-03-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an Item 2.02 section titled 'Results of Operations and Financial Condition' referencing a press release with financial results for the fourth quarter and fiscal year ended December 31, 2020, but the actual financial results are not included in this document. Instead, it states that the press release is furnished as an exhibit. Additionally, Item 5.02 announces the election of a new director and related compensatory arrangements. The document is not a full annual report (10-K) or an earnings release (ER) but rather a current report announcing events and furnishing a press release. Given the nature of the filing and the content, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document length (6672 characters) and content confirm it is not a brief announcement nor a full financial report but a current report with multiple announcements and a press release attached.
2021-03-11 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-19 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.